Stake Holders

Articles

Amid the COVID-19 pandemic, health professionals reported difficulty accessing  Parkinson disease medications, particularly in low-income countries, leading to greater disability of patients as a result.

Access to Parkinson Disease Medication Affected in Low-Income Countries

Patients of South Asian origins who have psoriatic arthritis have a worse clinical phenotype and worse disease impact than patients of North European origins, according to research published in Rheumatology.

Comparing Disease Impact and Activity in Psoriatic Arthritis by Ethnic Background

In individuals with type 2 diabetes with no previous insulin treatment, once-weekly injections of insulin icodec resulted in glucose-lowering efficacy and a safety profile similar to individuals who took once-daily insulin glargine U100. 

Phase 2 Trial Shows Weekly Insulin Injection Outcomes Similar to Daily Injections for T2D

To the extent that some factors are modifiable, the takeaway for clinicians is to encourage their patients with multiple sclerosis (MS) to adopt healthy habits.

Unraveling the Impact of Lifestyle, Genetics on MS

The drug, mastinib, reduced the chance of a confirmed disability progression by 37% in phase 2b/3 study results.

Tyrosine Kinase Inhibitor Shows Positive Results in Slowing Slide to MS Disability 

With more multiple sclerosis (MS) treatments becoming available, it is now possible to better personalize approaches, explained speakers during a session at MSVirtual 2020: 8th Joint ACTRIMS-ECTRIMS Meeting.

Choosing the Right MS Treatment by Customizing Therapy to the Individual

The broadest real-life study of dupilumab in atopic dermatitis (AD) found significant improvements in adults with moderate to severe AD that were even greater than the results reported in clinical trials.

Real-World Study: Dupilumab for Atopic Dermatitis More Effective Than Clinical Trial Results

In recent years, the number of children diagnosed with additional autoimmune diseases accompanying type 1 diabetes (T1D) has increased, according to a study published in Frontiers in Endocrinology. 

Study Highlights Prevalence of Comorbid Autoimmune Diseases, T1D in Pediatric Populations

Secukinumab 150 mg improves signs and symptoms of patients with nonradiographic axial spondyloarthritis, according to results of the PREVENT trial published in Arthritis & Rheumatology.

Secukinumab Significantly Improves Signs, Symptoms of Nonradiographic Axial Spondyloarthritis

Although the effects of stress and anger on ischemic heart disease and arrhythmia are well known, they are less established in heart failure, particularly those with reduced ejection fraction.

Academia

New content coming soon, please check back later.